adavosertib
astrazeneca
['ovarian', 'adavosertib', 'biomarker', 'astrazeneca']
adavorsertib, astrazeneca's wee1 inhibitor, may potentially benefit biomarker selected advanced ovarian cancer patients, as per the data presented in asco 2022. #astrazeneca #wee1 #asco #adavosertib #cancer #ovariancancer #health
PharmaScroll is a diligent business consulting and market research firm focused solely towards chronic disease indications.